BioNTech names new CEO Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 3 August, 2026

One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.

presented by Why Amer­i­ca's med­i­cine be­came a na­tion­al se­cu­ri­ty ques­tion

news Supernus, Indivior to merge and form CNS-focused drugmaker AstraZeneca, Bristol Myers in talks about merger — report BioNTech names Sobi's Guido Oelkers as incoming CEO Hackers steal patient data in Amgen cloud breach Exclusive: Dash Bio nets $30M for 'Amazon Web Services of drug development'

Aug 19 1:00 pm ET From pilots to production: AI across R&D, safety, regulatory, and clinical sponsored by IBM

Associate Director / Director, Preclinial Development - Immunology Terray Therapeutics, Inc. Monrovia, CA, USA Senior Director, Licensing Officer Bayer Cambridge, MA, USA Machine Learning Researchers and Engineers D. E. Shaw Research New York, NY, USA Scientist, Drug Discovery Data for AI/ML D. E. Shaw Research New York, NY, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

The China biotech story is moving fast. On Aug. 6, Endpoints hosts debate-style panels on how China's rise is forcing biotech to rethink innovation, live in Boston. Space is limited. Reserve your spot now.

ENDPOINTS PHARMA Skyrizi's momentum defies J&J's rival Icotyde as AbbVie raises full-year sales guidance Moderna delays norovirus vaccine trial readout because of too few infections Pharma groups back changes to 340B rebate pilot as earlier version remains stuck in court

in case you missed it 1. Novo Nordisk rocked by late-stage cardiovascular drug failure 2. Peer Review Ionis' top scientist Frank Bennett to retire; Recursion selects its first AI chief 3. Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer 4. Updated: Apnimed raises $192M in IPO for potential 2027 sleep apnea drug launch 5. News Briefing Ratio collects $70M for its radiopharmaceutical trials; Vogenx plans $67M IPO